Research Analysts Set Expectations for Assertio Q1 Earnings

Assertio Holdings, Inc. (NASDAQ:ASRT) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for Assertio in a report issued on Wednesday, March 18th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $0.19 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Assertio’s Q2 2027 earnings at $0.13 EPS, Q3 2027 earnings at $0.28 EPS, Q4 2027 earnings at $0.51 EPS and FY2027 earnings at $1.11 EPS.

Assertio (NASDAQ:ASRT) last posted its quarterly earnings data on Monday, March 16th. The company reported ($1.86) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.05) by $1.19. The business had revenue of $13.54 million during the quarter, compared to the consensus estimate of $6.20 million. Assertio had a negative return on equity of 30.26% and a negative net margin of 25.59%.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Assertio from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research downgraded shares of Assertio from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assertio in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Assertio presently has an average rating of “Hold” and a consensus target price of $35.00.

Assertio Trading Down 2.6%

NASDAQ ASRT opened at $13.37 on Monday. The firm has a market capitalization of $86.24 million, a PE ratio of -2.75 and a beta of 0.73. The business’s 50-day moving average price is $11.85 and its two-hundred day moving average price is $11.80. The company has a current ratio of 1.70, a quick ratio of 1.51 and a debt-to-equity ratio of 0.42. Assertio has a 12 month low of $7.65 and a 12 month high of $15.15.

Institutional Investors Weigh In On Assertio

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Assertio in the third quarter valued at approximately $26,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Assertio during the 4th quarter worth approximately $41,000. Rothschild Wealth LLC acquired a new stake in shares of Assertio during the 4th quarter worth approximately $172,000. Perritt Capital Management Inc increased its stake in shares of Assertio by 51.6% in the 3rd quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock valued at $309,000 after acquiring an additional 119,281 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its position in shares of Assertio by 536.0% during the 3rd quarter. GSA Capital Partners LLP now owns 381,584 shares of the company’s stock valued at $336,000 after acquiring an additional 321,584 shares during the period. 48.96% of the stock is currently owned by institutional investors.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.